Clinical Research Directory

Inclusion Criteria: * Biopsy proven adenocarcinoma of the prostate * Intermediate risk, organ-confined prostate cancer (T1a up to T2b) and voluntarily chooses Exablate, who may currently be on watchful waiting or active surveillance and not in need of imminent radical therapy * Up to 2 MRI visible Gleason 7 confirmed on mapping prostate biopsy that Investigator deems treatable within a single treatment session; may have secondary Gleason 6 on ipsilateral or contralateral side confirmed with biopsy and/or MRI * PSA less than or equal to 20ng/mL Exclusion Criteria: * Evidence of distant prostate cancer including lymph node involvement and/or metastasis of cancer * Subject undergoing androgen deprivation therapy, initiating any new medication that can affect PSA, or history of bilateral orchiectomy * Active bladder cancer, active UTI, or untreated prostatitis * Untreated urethral stricture/bladder neck contracture * Prostate-specific chemotherapy, brachytherapy, cryotherapy, photodynamic therapy, radical prostatectomy, or focal therapy (excluding FUS); or any prior radiation therapy to the pelvis for prostate cancer or any other malignancy * Subjects with pathology or implants that may adversely impact treatment due to acoustics, imaging, or safe probe insertion * Subject not able or willing to tolerate the required prolonged stationary supine position during treatment * Contraindications to MRI